Company: PRME
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001193125-25-122158
Chunk: 5

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 5
---
 executives. In addition, in the event Dr. Reine
is terminated by us without cause or he resigns for good reason, in each case within eighteen (18) months following a “Change in Control,” all of the then-outstanding and unvested portion of his stock options and other stock-based
awards that are subject solely to time-based vesting shall become fully vested and exercisable or non-forfeitable immediately as of the date of termination, with any such performance-based awards vesting at
target.

Pursuant to the Reine Employment Agreement, the Board approved the grant of a stock option to purchase up to 2,000,000 shares of the
Company’s common stock, par value $0.00001 per share (“Common Stock”), pursuant to the Company’s 2022 Stock Option and Incentive Plan (the “2022 Plan”) to Dr. Reine. The stock option award will have an exercise
price equal to the closing price of the Company’s common stock on the Nasdaq Global Market on the date of grant. Twenty-five percent of the shares will vest on the one-year anniversary of the date of the
grant and the balance will vest monthly in equal installments over the following thirty-six (36) months, subject to Dr. Reine’s continuous service. In addition, the Board approved the grant of a
stock option to purchase up to 500,000 shares of Common Stock pursuant to the Plan to Dr. Reine. The stock option award will have an exercise price equal to the closing price of Common Stock on the Nasdaq Global Market on the date of grant and
will vest upon the achievement of agreed milestones that will be set forth in the applicable equity agreement, subject to Dr. Reine’s continuous service.

Dr. Reine has also entered into the Company’s standard form of director indemnification agreement, which was filed as Exhibit 10.7 to the
Company’s Registration Statement on Form S-1/A filed on October 17, 2022.

There is no arrangement or
understanding between Dr. Reine and any other person pursuant to which he was selected as an officer and director of the Company, and there are no family relationships between Dr. Reine and any of the Company’s directors or executive
officers. There are no transactions to which the Company is a party and in which Dr. Reine has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation
S-K